Pharmacokinetic drug-drug interactions with methotrexate in oncology

Expert Review of Clinical Pharmacology

Volumn 4, Issue 6, 2011, Pages 743-750

  Levêque, Dominique ^a   Santucci, Raoul ^a   Gourieux, Bénédicte ^a   Herbrecht, Raoul ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

drug transporter; drug drug interaction; methotrexate; oncology; pharmacokinetics

Indexed keywords

AMOXICILLIN; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; FOLINIC ACID; GEMFIBROZIL; IMATINIB; KETOPROFEN; LANSOPRAZOLE; METHOTREXATE; MEZLOCILLIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; OMEPRAZOLE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 4; PANTOPRAZOLE; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; PROBENECID; RABEPRAZOLE; REDUCED FOLATE CARRIER; UNINDEXED DRUG; VANCOMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; DEATH; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TRANSPORT; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLIOMA; GLOMERULUS FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; ONCOLOGY; OSTEOSARCOMA; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG INTERACTIONS; HUMANS; MEDICAL ONCOLOGY; METHOTREXATE; NEOPLASMS; ORGANIC ANION TRANSPORTERS;

EID: 80155142288     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.57     Document Type: Review

References (58)

1. Chabner B, Roberts Jr TG. Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72 (2005). (Pubitemid 40052326)
2. Crom WR. Methotrexate. In: A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Grochow LB, Ames MM (Eds). Williams & Wilkins, MD, USA, 311-330 (1998).
3. Messmann RA, Allegra CJ. Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds). Lippincott Williams & Wilkins, PA, USA, 139-184 (2001).
4. Buchen S, Ngampolo D, Melton RG et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer 92, 480-487 (2005). (Pubitemid 40395528)
5. Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J. Clin. Pharm. Ther. 33, 677-684 (2008).
6. Trevino LR, Shimasaki N, Yang W et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972-5978 (2009).
7. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukaemia. Pediatr. Blood Cancer 57, 612-619 (2011).
8. Crews KR, Liu T, Rodriguez-Galindo C et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100, 1724-1733 (2004). (Pubitemid 38456352)
9. Giacomini KM, Huang S-M, Tweedie DJ et al.; for the the International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discover. 9, 215-236 (2010).
10. Mutsaers HAM, van den Heuvel LB, Ringens LH et al. Uremic toxins inhibit transport by breast resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PloS One 6, e18438 (2011).
11. Abe T, Unno M, Onogawa T et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120, 1689-1699 (2001). (Pubitemid 32523487)
12. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol. 66, 450-459 (2004). (Pubitemid 39329243)
13. van de Steeg E, van der Kruijssen CM, Wagenaar E et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos. 37, 277-281 (2009).
14. Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59, 2532-2535 (1999). (Pubitemid 29269093)
15. Ito KI, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SPC. Mutation of Trp1254 in the multispecific organic anion transporter multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem. 276, 38108-38114 (2001).
16. Hulo JS, Villard E, Maguy A et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics 15, 277-285 (2005). (Pubitemid 40676548)
17. Chen ZC, Lee K, Walther S et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62, 3144-3150 (2002). (Pubitemid 34602407)
18. Kool M, van der Linden M, de Haas M et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl Acad. Sci. USA 96, 6914-6919 (1999). (Pubitemid 29274984)
19. Breedveld P, Zelcer N, Pluim D et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug- drug interactions. Cancer Res. 64, 5804-5811 (2004). (Pubitemid 39095580)
20. Cha SH, Sekine T, Fukushima JI et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59, 1277-1286 (2001). (Pubitemid 32385197)
21. Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302, 666-671 (2002). (Pubitemid 34787234)
22. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther. 309, 226-234 (2004). (Pubitemid 38393134)
23. Richelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl Cancer Inst. 99, 592-600 (2007). (Pubitemid 47073540)
24. Lemachatti J, Leveque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumour drug disposition in cancer patients. Anticancer Res. 29, 4741-4744 (2009).
25. Benet L, Hoerner BA. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002). (Pubitemid 34271114)
26. Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J. Rheumatol. 37, 1416-1421 (2010).
27. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1, 256-258 (1986). (Pubitemid 16132863)
28. Nozaki Y, Kusuhara H, Kondo T et al. Species differences in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther. 322, 1162-1170 (2007).
29. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP)2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320, 229-235 (2007). (Pubitemid 46025738)
30. Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am. J. Pediatr. Hematol. Oncol. 14, 88-89 (1992).
31. Ronchera CL, Hernandez T, Peris JE et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther. Drug Monit. 15, 375-379 (1993). (Pubitemid 23297239)
32. Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann. Pharmacother. 31, 1261-1262 (1997). (Pubitemid 27431080)
33. Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J. Antimicrob. Chemother. 58, 228-230 (2006). (Pubitemid 44295021)
34. de Miguel D, Garcia-Suarez J, Martin Y, Gil-Fernandez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol. Dial. Transplant 23, 3762-3766 (2008).
35. Titier K, Lagrange F, Pehourcq F, Moore N, Molimard M. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther. Drug Monit. 24, 570-572 (2002). (Pubitemid 34857914)
36. Dalle J-H, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J. Pediatr. Hematol. Oncol. 24, 321-322 (2002). (Pubitemid 34506624)
37. Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann. Oncol. 13, 327-330 (2002). (Pubitemid 34704988)
38. Thyss A, Milano G, Renee N, Cassuto- Viguier E, Jambou P, Soler C. Severe interaction between methotrexate and a macrolide-like antibiotic. J. Natl Cancer Inst. 85, 582-583 (1993). (Pubitemid 23110935)
39. Shamash J, Joel S, Lundholm L, Millard L, Oliver T. High-dose methotrexate clearance following prior vancomycin administration: no significant interaction in the absence of overt renal impairment. Ann. Oncol. 43, 169-170 (2003). (Pubitemid 36150276)
40. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination. Am. J. Med. 123, 182.e1-182.e7 (2010).
41. Seithel A, Eberl S, Singer K et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos. 35, 779-786 (2007). (Pubitemid 46641549)
42. Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother. Pharmacol. 33, 82-84 (1993). (Pubitemid 23336506)
43. Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate. Cancer Chemother. Pharmacol. 33, 88-89 (1999). (Pubitemid 29246330)
44. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann. Pharmacother. 34, 1024-1027 (2000). (Pubitemid 30660780)
45. Troger U, Stotzel B, Martens- Lobenhoffer J, Gollnick H, Meter FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br. Med. J. 324, 1497 (2002). (Pubitemid 34666620)
46. Joerger M, Huitema A, Van den Bongard H et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br. J. Clin. Pharmacol. 62, 71-80 (2005). (Pubitemid 44195244)
47. Bauters TGM, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm. World Sci. 30, 316-318 (2008).
48. Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 67, 44-49 (2009).
49. Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 30, 3807-3810 (2010).
50. Santucci R, Leveque D, Kemmel V et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res. 30, 963-966 (2010).
51. Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. J. Med. 1, 1097-1099 (1978). (Pubitemid 8319298)
52. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6) mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug- drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004). (Pubitemid 39287802)
53. Watanabe T, Kusuhara H, Watanabe T et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos. 39, 1031-1038 (2011).
54. van Hest RM, Schnog JB, van't Veer MB, Cornelissen JJ. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated by imatinib. Am. J. Hematol. 83, 757-758 (2008).
55. Scholler J, Leveque D. Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncol. Rev. 5, 77-92 (2011).
56. Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285-290 (2000). (Pubitemid 30459586)
57. Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J. Neurooncol. 48, 249-250 (2000).
58. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated by carbamazepine. Clin. Pharmacol. Ther. 80, 440-456 (2006).